Schwannoma clinical trials at UC Cancer
3 research studies open to eligible people
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
open to eligible people ages 12 years and up
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2 to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. - Investigational Drug Sub-study A: Brigatinib - Investigational Drug Sub-study B: Neratinib
Intraoperative Electrically-evoked ABRs in Patients Undergoing Vestibular Schwannoma Surgery
open to eligible people ages 18-99
This is a study of the feasibility of activating the auditory system by an electrode in direct contact with the cochlear nerve.
at UC Irvine
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
open to eligible people ages 18 years and up
In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.
Our lead scientists for Schwannoma research studies include John C Middlebrooks, PhD Harrison M Lin, MD.